Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

CVL 047

Next Previous
Search
Drug Profile

CVL 047

Alternative Names: CVL-047; PDE4b inhibitor - Cerevel Therapeutics

Latest Information Update: 05 Aug 2024

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Pfizer
  • Developer Cerevel Therapeutics
  • Class Antidepressants; Antipsychotics
  • Mechanism of Action Type 4 cyclic nucleotide phosphodiesterase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes
  • Available For Licensing Yes

Highest Development Phases

  • Preclinical Major depressive disorder
  • No development reported Schizophrenia

Most Recent Events

  • 01 Aug 2024 Cerevel Therapeutics has been acquired by AbbVie
  • 28 Apr 2024 No recent reports of development identified for preclinical development in Schizophrenia in USA
  • 31 Dec 2021 Cerevel Therapeutics has patent protection for CVL 047 in the United States, foreign jurisdictions, including Canada, China, Japan and in various member states of the European Patent Office prior to December 2021

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top